Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease.

Suppr

超能文献

作者信息

Muenter M D, Sharpless N S, Tyce G M

出版信息

Mayo Clin Proc. 1972 Jun;47(6):389-95.

PMID:5041685

Abstract

摘要

相似文献

Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease.

Mayo Clin Proc. 1972 Jun;47(6):389-95.

3-methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson's disease.

Clin Chim Acta. 1972 Mar;37:359-69. doi: 10.1016/0009-8981(72)90456-1.

[Therapy of parkinsonian syndromes and plasmatic DOPA levels. Effects of L-DOPA and 3-OMD, administered alone or combined, with or without a decarboxylase inhibitor].

Rev Eur Etud Clin Biol. 1972 Jan;17(1):38-44.

L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects.帕金森病的左旋多巴治疗：血浆左旋多巴浓度、治疗反应及副作用。

Mayo Clin Proc. 1971 Apr;46(4):231-9.

3-O-Methyldopa, L-dopa, and trihexyphenidyl in the treatment of Parkinson's disease.

Mayo Clin Proc. 1973 Mar;48(3):173-83.

Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease.帕金森病左旋多巴治疗期间的高香草酸（HVA）和5-羟吲哚乙酸（5HIAA）

Neurology. 1970 Apr;20(4):377.

[Parkinsonism and plasma metabolism of dihydroxyphenylalanine administered with an inhibitor of decarboxylase].

Clin Chim Acta. 1971 Jun;33(1):111-5. doi: 10.1016/0009-8981(71)90257-9.

[Study of 3-4-dihydroxyphenylacetic acid, a dopamine catabolite, in patients with Parkinson's disease before treatment with L-dopa].

Rev Neurol (Paris). 1972 Aug;127(2):315-7.

Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486).α-甲基多巴肼（MK-486）对帕金森病左旋多巴治疗的改良作用

Trans Am Neurol Assoc. 1971;96:55-8.

Alpha-methyldopa as an adjunct to levodopa treatment of Parkinson's disease.

Trans Am Neurol Assoc. 1971;96:59-65.

引用本文的文献

The role of 3-O-methyldopa in the side effects of L-dopa.3 - O - 甲基多巴在左旋多巴副作用中的作用。

Neurochem Res. 2008 Mar;33(3):401-11. doi: 10.1007/s11064-007-9442-6. Epub 2007 Aug 24.

Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease.左旋多巴药代动力学中个体内变异的重要性：一项针对帕金森病的4年队列研究

J Pharmacokinet Pharmacodyn. 2005 Aug;32(3-4):307-31. doi: 10.1007/s10928-005-0039-x.

Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice.儿茶酚-O-甲基转移酶/单胺氧化酶抑制剂与左旋多巴在MPTP处理小鼠中的协同相互作用。

J Neural Transm Gen Sect. 1995;102(1):19-34. doi: 10.1007/BF01276562.

Low catechol-O-methyltransferase activity in a Saami population.萨米人群中儿茶酚-O-甲基转移酶活性较低。

Eur J Clin Pharmacol. 1994;46(3):231-5. doi: 10.1007/BF00192554.

Substantia nigra degeneration and tyrosine hydroxylase depletion caused by excess S-adenosylmethionine in the rat brain. Support for an excess methylation hypothesis for parkinsonism.大鼠脑中过量S-腺苷甲硫氨酸导致黑质变性和酪氨酸羟化酶耗竭。对帕金森病甲基化过量假说的支持。

Mol Neurobiol. 1994 Aug-Dec;9(1-3):149-61. doi: 10.1007/BF02816115.

Catechol-O-methyltransferase inhibition by U-0521 increases striatal utilization of levodopa.

Naunyn Schmiedebergs Arch Pharmacol. 1982 Jul;320(1):34-7. doi: 10.1007/BF00499068.

Clinical pharmacokinetics of anti-parkinsonian drugs.抗帕金森病药物的临床药代动力学

Clin Pharmacokinet. 1987 Sep;13(3):141-78. doi: 10.2165/00003088-198713030-00002.

Parkinsonian abnormality of foot strike: a phenomenon of ageing and/or one responsive to levodopa therapy?帕金森病足跟着地异常：一种衰老现象和/或对左旋多巴治疗有反应的现象？

Br J Clin Pharmacol. 1990 Feb;29(2):179-86. doi: 10.1111/j.1365-2125.1990.tb03617.x.

Effect of duration of levodopa/decarboxylase inhibitor therapy on the pharmacokinetic handling of levodopa in elderly patients with idiopathic Parkinson's disease.左旋多巴/脱羧酶抑制剂治疗时长对老年特发性帕金森病患者左旋多巴药代动力学处理的影响。

Eur J Clin Pharmacol. 1991;41(5):459-62. doi: 10.1007/BF00626369.

Gout induced by L-dopa and decarboxylase inhibitors.左旋多巴和脱羧酶抑制剂诱发的痛风。

Postgrad Med J. 1976 Apr;52(606):232-3. doi: 10.1136/pgmj.52.606.232.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验